Developing computer models for combination therapy in aggressive lymphomas
Official title: Modeling and analysis of curative combination therapy for Diffuse Large B-Cell Lymphoma
Funded at Univ of North Carolina Chapel Hill · NIH-11017031 · Data updated 2026-11-12
This study is looking at how different combinations of drugs can work together to treat Diffuse Large B-Cell Lymphoma (DLBCL) better, using computer simulations to understand how these treatments might affect different patients and their unique tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $344,581 |
| NIH project number | 5R01CA279968-02 |
| Project ID | NIH-11017031 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Diffuse Large B-Cell Lymphoma who are seeking advanced treatment options.
✕Less likely to help
Patients with other types of cancers or those who do not have Diffuse Large B-Cell Lymphoma may not benefit from this research.
What this research studies
This research focuses on creating advanced computer simulations to analyze combination therapies for Diffuse Large B-Cell Lymphoma (DLBCL). By understanding how different drugs interact and how tumors respond to these treatments, the research aims to improve the design of new treatment regimens. The simulations will take into account the variability among patients and the complexity of tumors, which can differ significantly from one individual to another. This approach seeks to enhance the effectiveness of therapies by predicting how various combinations of drugs will work in diverse patient populations.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with aggressive lymphomas.
How similar studies have gone: Previous research using similar modeling approaches has successfully predicted treatment responses in solid cancers, leading to multiple FDA drug approvals.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Palmer, Adam Christopher — Univ of North Carolina Chapel Hill
- Study coordinator: Palmer, Adam Christopher
Related research
Other NIH-funded projects on the same topics.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
-
Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
-
Lowering c-Myc to treat aggressive large B‑cell lymphoma
This work develops drugs that make the cancer protein c‑Myc break down, aiming to help people with aggressive large B‑cell lymphoma that overproduce c‑Myc.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.